| Ytd | -50.59% | |
| 1y | -7.40% |
| Open | 6.92 | Prev Close | 7.06 | Low | 6.91 | High | 7.11 | Mkt Cap | 14.24M |
| Vol | 21.73K | Avg Vol | 757.58K | EPS | -5.67 | P/E | N/A | Forward P/E | -0.43 |
| Beta | 1.51 | Short Ratio | 0.20 | Inst. Own | 5.89% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 5.37 | 200-d Avg | 7.37 | 1yr Est | 4.50 |
QNRX News
Gainers AEON Biopharma (AMEX:AEON) stock moved upwards by 8.9% to $0.32 during Thursday's after
Second Rare Pediatric Disease (RPD) Designation for QRX003FDA Previously Granted RPD Designation for
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular
US stocks up, Dow gains 100 points, S&P 500 and NASDAQ also rise. Communication services up 1.1%
Shares of Quoin Pharmaceuticals are rallying Friday after pre-market updates on positive trial resul
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-mark
AFRM: 13% | Affirm Holdings shares are trading higher after the company reported strong Q4 financial
Elastic NV (ESTC) stock rose 21.8% in pre-market trading after reporting strong Q1 results and raisi
Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.90) per share which missed the
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 41.1% to $0.09 during Frida
Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Pa
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinica
Gainers Pulsenmore (NASDAQ:PLSM) stock increased by 152.0% to $8.59 during Wednesday's pre-mark
Leifras Co Ltd (NASDAQ: LFS) rose in pre-market trading after acquiring SWIFT JAPAN for JPY454.6 mil
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical
The formation follows the recent grant of Orphan Drug Designation to QRX003 by Japan's Ministry
Six pediatric NS patients are currently enrolled in the program, all under 10 years of age, with the
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical
The IND submission is supported by clinical observations from Quoin's ongoing investigator-led p
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.77) per share which missed the
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNR
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.74) per share which beat the an
FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinica
